

Maryam Ehteshami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6796759/publications.pdf>

Version: 2024-02-01

14
papers

394
citations

840776

11
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

750
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracellular metabolism and potential cardiotoxicity of a $\hat{1}^2$ -D-2 $\hat{2}$ -C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 204-224.	1.1	3
2	Discovery of a Series of 2 $\hat{2}$ - $\hat{1}$ -Fluoro,2 $\hat{2}$ - $\hat{1}^2$ -bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1859-1874.	6.4	11
3	Towards $\langle \text{sc} \rangle \text{HBV} \langle / \text{sc} \rangle$ curative therapies. <i>Liver International</i> , 2018, 38, 102-114.	3.9	63
4	Metabolism of Nucleosides and Nucleotides Prodrugs. <i>Current Pharmaceutical Design</i> , 2018, 23, 6984-7002.	1.9	8
5	Characterization of $\hat{1}^2$ - $\langle \text{sc} \rangle \text{d} \langle / \text{sc} \rangle$ - $\langle \text{i} \rangle \text{N} \langle / \text{i} \rangle$ $\langle \text{sup} \rangle 4 \langle / \text{sup} \rangle$ -Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	64
6	2 $\hat{2}$ -Chloro,2 $\hat{2}$ -fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5424-5437.	6.4	23
7	Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	8
8	Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4659-4669.	3.2	11
9	Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. <i>Clinics in Liver Disease</i> , 2016, 20, 737-749.	2.1	24
10	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4101-4105.	2.2	13
11	Synthesis and Evaluation of 2,6-Modified Purine 2 $\hat{2}$ - $\langle \text{i} \rangle \text{C} \langle / \text{i} \rangle$ -Methyl Ribonucleosides as Inhibitors of HCV Replication. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 17-22.	2.8	16
12	$\hat{1}^2$ - $\langle \text{sc} \rangle \text{d} \langle / \text{sc} \rangle$ -2 $\hat{2}$ - $\langle \text{i} \rangle \text{C} \langle / \text{i} \rangle$ -Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5 $\hat{2}$ -Triphosphate Forms. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3445-3458.	6.4	30
13	Chutes and ladders in hepatitis C nucleoside drug development. <i>Antiviral Research</i> , 2014, 102, 119-147.	4.1	69
14	Approaches to hepatitis C treatment and cure using NS5A inhibitors. <i>Infection and Drug Resistance</i> , 2014, 7, 41.	2.7	51